Merck’s Q3 sales rose +7% to €3,121m and the gross profit margin improved from 67.5% to 69.9%. EBITDA strongly increased (+15% to €901m), partly helped by higher D/A, and net profit attributable to shareholders jumped +46% to €364m. Operating CF increased +20% to €872m driven by the stronger operating performance and reporting higher NWC inflow (€158m after €128m). Investing CF swung from €-364m to €418m seeing much lower investments in financial
12 Nov 2015
Healthcare’s continued weak dynamics
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Healthcare’s continued weak dynamics
Merck KGaA (MRCK:WBO) | 0 0 1.2% | Mkt Cap: 10,792m
- Published:
12 Nov 2015 -
Author:
Martin Schnee -
Pages:
3
Merck’s Q3 sales rose +7% to €3,121m and the gross profit margin improved from 67.5% to 69.9%. EBITDA strongly increased (+15% to €901m), partly helped by higher D/A, and net profit attributable to shareholders jumped +46% to €364m. Operating CF increased +20% to €872m driven by the stronger operating performance and reporting higher NWC inflow (€158m after €128m). Investing CF swung from €-364m to €418m seeing much lower investments in financial